ORRs∗ and CR/CRi rates over follow-up period in patients treated with A-O or A monotherapy. ∗Best investigator-assessed response could be determined at any scheduled, per-protocol follow-up visit. ORR is defined as achieving CR, CRi, nPR, or PR per the investigator per International Workshop on CLL 2008 criteria²¹ at or before initiation of subsequent anticancer therapy. ORR does not include partial response except for lymphocytes. A, acalabrutinib; nPR, nodular partial response; O, obinutuzumab; PR, partial response.